{
  "id": 11469399,
  "title": "Lilly, Foghorn part ways; Wave’s FDA-approved plans",
  "url": "https://urgent.news/2026/10/01/lilly-foghorn-part-ways-waves-fda-approved-plans",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T16:04:53.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/foghorn-eli-lilly-wave-samsung-bioepis-teva-varda-hatteras/831918/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}